The EDC3 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma cell line. This product provides a heterogeneous pool of cells carrying targeted disruption of the EDC3 gene, enabling robust loss-of-function studies in an epithelial background relevant to intestinal biology and colorectal cancer. Unlike clonal lines, the polyclonal format preserves genetic diversity, reflecting the complex editing outcomes encountered in pooled screening approaches and facilitating the study of gene function in a more physiologically variable context.
The HT29 host cell line is a widely characterized model of human colorectal adenocarcinoma, established from a primary tumor of a 44-year-old Caucasian female. These cells exhibit an adherent epithelial morphology and are known for their ability to differentiate into enterocyte-like cells under post-confluent conditions, making them a valuable system for investigating colonocyte biology, drug absorption, and metabolic transformation. HT29 cells harbor mutations in key oncogenes and tumor suppressors (e.g., BRAF V600E, PIK3CA, TP53), providing a clinically relevant genomic background for dissecting signaling pathways and therapeutic responses in colorectal cancer.
EDC3 encodes a central scaffold protein of the mRNA decapping machinery, enhancing the DCP1-DCP2-mediated removal of the 5?? cap structure to initiate 5??C3?? decay. It interacts directly with decapping factors including DCP1A, DCP2, DDX6, EDC4, LSM14A, and PATL1, facilitating P-body assembly and coordinated mRNA turnover. EDC3 function is regulated by upstream kinases such as mTORC1 and p38 MAPK and is responsive to stress signals (e.g., arsenite, nutrient starvation). Its disruption leads to stabilization of short-lived transcripts, notably oncogenes like FOS, MYC, and CCND1, which can drive proliferation and survival programs. Consequently, EDC3 knockout in HT29 cells allows interrogation of how decapping dysfunction alters the expression of these critical factors.
In the colorectal cancer context, impaired EDC3 activity may contribute to aberrant mRNA stabilization, potentially fueling oncogenesis and modulating drug sensitivity. Given that EDC3 mutations have been linked to neurodevelopmental disorders, this model also provides a platform to explore tissue-specific roles of mRNA decay pathways. The polyclonal knockout population is particularly suited for studying heterogeneity in stress response, P-body dynamics, and transcriptome-wide changes without the artifacts of clonal selection, offering a more representative system for functional genomics and drug discovery applications.
Typical experimental applications include RNA-sequencing to identify EDC3-dependent transcripts, RT-qPCR validation of target mRNA half-lives, western blotting for EDC3 protein depletion, and immunofluorescence analysis of P-body components (e.g., DDX6, LSM14A). Functional assays such as cell proliferation, apoptosis, and sensitivity to 5?fluorouracil can be employed to evaluate the therapeutic relevance of mRNA decapping in colorectal cancer. For further information regarding this product, please contact Ascent Research.
